SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

GRANULES INDIA

BSE: 532482 29 Jun 2025
Healthcare
₹ 497.45
Granules India Ltd. specializes in Pharmaceuticals within the Healthcare sector.

GRANULES INDIA - Share Price & Details

Market Cap
₹12,064
High /Low
725.0 / 412.0
Stock P/E
25.2
Book Value
₹153.0
Dividend Yield
0.3
ROCE
15.1
ROE
₹13.8
Face Value
1.0
PEG Ratio
2.89
EVEBITDA
₹13.5
Debt
1,455
CMP / FCF
52.8
Debt to equity
₹0.39
NP Ann
502
High price all time
725.0
Piotroski score
₹7.0
Graham Number
267.0
No. Eq. Shares
24.3
Net CF
₹82.8
Net profit
502
Price to book value
3.25
Interest Coverage
₹7.1
Low price all time
2.53
Industry PE
32.7
Reserves
₹3,691
Free Cash Flow
₹297

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
GRANULES INDIA LTD.NANANANA12,06425.2
MARKSANS PHARMA LTD.3071.74375.912993.570.831144530.1
Vijaya Diagnostic Centre Limit1655.33331.191598.523.221016270.6

Peer Comparison Chart


About GRANULES INDIA

Granules India Ltd., with Security Code 532482, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Granules India Ltd receives 1 observation from USFDA for Chantilly facility

(29 Jun 2025)
The US FDA has completed a Pre-Approval Inspection for a first to file controlled substance ANDA at the facility of Granules Pharmaceuticals...
Read more →

Granules India Shares Gain 2% on 1 Observation from USFDA

(24 Jun 2025)
Shares of Granules India Ltd were trading 2% higher on 23 June after the company announced receiving one observation from the US FDA for its...
Read more →

Stocks to watch: HAL, MakeMyTrip, ONGC, Zen Tech, Bank of India, BEL shares in focus

(23 Jun 2025)
Indian share market is expected to see gap-down opening on Monday, tracking negative cues from Asian stocks and weak trend in Gift Nifty...
Read more →

Granules India's Bonthapally facility completes US FDA inspection with one observation

(22 Jun 2025)
Granules India Ltd on Friday said its API Unit-I facility at Bonthapally, Telangana has completed a U.S. Food and Drug Administration (US...
Read more →

Granules Indias API Facility In Telangana Gets FDA Observation

(22 Jun 2025)
Granules India Ltd.'s active pharmaceutical ingredient facility in Telangana received an observation from the US Food and Drugs...
Read more →

Granules India Wraps Up USFDA Inspection at Bonthapally with Single Observation

(22 Jun 2025)
Granules India Ltd informed the exchanges on Friday that the U.S. FDA has completed its inspection of the company's API Unit-I at...
Read more →